A New antiarrhythmic drug in the treatment of recent-onset atrial fibrillation: Vernakalant

Cardiovascular Therapeutics

Volumn 31, Issue 5, 2013, Pages

  Vizzardi, Enrico ^a   Salghetti, Francesca ^a   Bonadei, Ivano ^a   Gelsomino, Sandro ^b   Lorusso, Roberto ^c   D'Aloia, Antonio ^a   Curnis, Antonio ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Diagnostic Genetic Unit   (United States)

^c Civic Hospital   (Italy)

Author keywords

Atrial fibrillation; Cardioversion; Vernakalant

Indexed keywords

AMIODARONE; FLECAINIDE; PLACEBO; VERNAKALANT;

ATRIOVENTRICULAR BLOCK; CLINICAL TRIAL; DRUG MECHANISM; DYSGEUSIA; HEART ATRIUM CONDUCTION; HEART ATRIUM FIBRILLATION; HEART MUSCLE REFRACTORY PERIOD; HEART VENTRICLE FIBRILLATION; HUMAN; HYPOTENSION; NONHUMAN; PARESTHESIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINUS ARREST; SINUS BRADYCARDIA; SNEEZING;

ATRIAL FIBRILLATION; CARDIOVERSION; VERNAKALANT;

ADMINISTRATION, ORAL; ANISOLES; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; HUMANS; PYRROLIDINES;

EID: 84883766096     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12026     Document Type: Review

References (37)

1. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31(19):2369-2429.
2. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012b;33(21):2719-2747.
3. Bellandi F, Dabizzi RP, Cantini F, Natale MD, Niccoli L. Intravenous propafenone: Efficacy and safety in the conversion to sinus rhythm of recent onset atrial fibrillation-a single-blind placebo-controlled study. Cardiovasc Drugs Ther 1996;10:153-157.
4. Boriani G, Capucci A, Lenzi T, Sanguinetti M, Magnani B. Propafenone for conversion of recent-onset atrial fibrillation. A controlled comparison between oral loading dose and intravenous administration. Chest 1995;108:355-358.
5. Reisinger J, Gatterer E, Lang W, et al. Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset. Eur Heart J 2004;25:1318-1324.
6. Abi-Mansour P, Carberry PA, McCowan RJ, Henthorn RW, Dunn GH, Perry KT. Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter and atrial fibrillation. Am Heart 1998;136:632-642.
7. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT, for the Ibutilide Repeat Dose Study Investigators. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996;94:1613-1621.
8. Volgman AS, Carberry PA, Stambler B, et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol 1998;31:1414-1419.
9. Vos MA, Golitsyn SR, Stangl K, et al. for the Ibutilide/Sotalol Comparator Study Group. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. Heart 1998;79:568-575.
10. Khan IA, Mehta NJ, Gowda RM. Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol 2003;89(2-3):239-248.
11. Cheng JW, Rybak I. Pharmacotherapy options in atrial fibrillation: Focus on vernakalant. Clin Med Ther 2009;1:215-230.
12. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 1992;20:527-532.
13. Singh BN, Wadhani N. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs. J Cardiovasc Pharmacol Ther 2004;9(Suppl 1):S85-S97.
14. Beatch GN, Lin S, Hesketh JC, Johnson BD, Ezrin AM, Fedida D. Electrophysiological mechanism of RSD1235, a new atrial fibrillation converting drug. Circulation 2003;108(Suppl IV):85.
15. Fedida D, Orth PM, Chen JY, et al. The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol 2005;16(11):1227-1238.
16. Tian D, Frishman WH. Vernakalant: A new drug to treat patients with acute onset atrial fibrillation. Cardiol Rev 2011;19(1):41-44.
17. Naccarelli GV, Wolbrette DL, Samii S, Banchs JE, Penny-Peterson E, Stevenson R, Gonzalez MD. Vernakalant-a promising therapy for conversion of recent-onset atrial fibrillation. Expert Opin Investig Drugs 2008;17(5):805-810.
18. Jost N, Viràg L, Hàla O, Varrò A, Thormahlen D, Papp JG. Effect of the antifibrillatory compound tedisamil (KC-8857) on transmembrane currents in mammalian ventricular myocytes. Curr Med Chem 2004;11:3219-3228.
19. Yang T, Snyders DJ, Roden DM, et al. Ibutilide, a methanesulfonanilide antiarrhythmic, is a potent blocker of the rapidly activation delayed rectifier K+ currently (Ikr) in AT-1 cells. Circulation 1995;91:1799-1806.
20. Roy D, Rowe BH, Stiell IG, et al. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol 2004;12:2355-2361.
21. Creswell LL, Schuessler RB, Rosenbloom M, Cox JL. Hazards of postoperative atrial arrhythmias. Ann Thorac Surg 1993;56:539-549.
22. Roy D, Pratt CM, Torp-Pedersen C, et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: A phase 3, randomized, placebo-controlled trial. Circulation 2008;117(12):1518-1525.
23. Pratt CM, Roy D, Torp-Pedersen C, et al. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation. Am J Cardiol 2010;106(9):1277-1283.
24. Stiell IG, Roos JS, Kavanagh KM, Dickinson G. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm. Am Heart J 2010;159(6):1095-1101.
25. Assessment report for Brinavess. International nonproprietary name: vernakalant. London, United Kingdom: European Medicine Agency; 2011. p. 3-57
26. Mariscalco G, Engström KG. Atrial fibrillation after cardiac surgery: Risk factors and their temporal relationship in prophylactic drug strategy decision. Int J Cardiol 2008;129:354-362.
27. Maisel WH, Rawn JD, Stevenson WG. Atrial fibrillation after cardiac surgery. Ann Intern Med 2001;135:1061-1073.
28. Kowey PR, Dorian P, Mitchell LB, et al. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: A randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol 2009;2(6):652-659.
29. Camm AJ, Toft E, Torp-Pedersen C, et al. Efficacy and safety of vernakalant in patients with atrial flutter: A randomized, double-blind, placebo-controlled trial. Europace 2012;14(6):804-809.
30. Camm AJ, Capucci A, Hohnloser SH, Torp-Pedersen C, Van GelderIC, Mangal B, Beatch G, AVRO Investigators. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol 2011;3:313-321.
31. Siddoway LA. Amiodarone: Guidelines for use and monitoring. Am Fam Physician 2003;68:2189-2196.
32. Vardas PE, Kochiadakis GE, Igoumenidis NE, Tsatsakis AM, Simantirakis EN, Chlouverakis GI. Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: A randomized, controlled study. Chest 2000;117:1538-1545.
33. Torp-Pedersen C, Raev DH, Dickinson G, Butterfield NN, Mangal B, Beatch GN. A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion. Circ Arrhythm Electrophysiol 2011;4(5):637-643.
34. Bash LD, Buono JL, Davies GM, et al. Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation. Cardiovasc Drugs Ther 2012;26(2):167-179.
35. Cardiome. Cardiome announces suspension of enrollment in ACT 5 trial, 21 October 2010. http://cardiome.com/wordpress (Web site accessed on 19/01/2013)
36. Buccelletti F, Iacomini P, Botta G. et al. Efficacy and safety of vernakalant in recent-onset atrial fibrillation after the european medicines agency approval. Systematic review and meta-analysis: J Clin Pharmacol 2012;52(12):1872-1878.
37. Revised Summary of Product Characteristics (SPC) for vernakalant (Brinavess) Brinavess EMEA/H/C/1215/II/007 http://www.cbg-meb.nl/NR/rdonlyres/CA9EADC9-8FAD-4C0E-965A-29E4D168681D/0/1203DHPCBrinavessEN.pdf. (Web site accessed on 12 August 2012)